Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation‐predominant irritable bowel syndrome

Abstract

Renzapride is well-tolerated, stimulates gastrointestinal transit and improves symptoms in patients with constipation-predominant irritable bowel syndrome, particularly at the 2 mg b.d. dose, where improvements in gastrointestinal symptoms were evident over placebo. This study has established proof of concept and supports further investigation of renzapride in patients with constipation-predominant irritable bowel syndrome.